临床概况和痴呆症的模式在老年中心
O O Elugbadebo1, T H Farombi2, O A Afolabi3
1Department of Psychiatry, College of Medicine, University of Ibadan, Nigeria.
Annals of Ibadan postgraduate medicine
|June 28, 2024
概括
低收入国家的痴呆症患者往往有多种健康问题,并迟迟寻求治疗. 了解他们的个人资料是改善痴呆症护理和早期发现的关键.
科学领域:
- 老年医学 老年医学
- 神经学 神经学
- 公共卫生 公共卫生
背景情况:
- 痴呆症的临床表现知识对于护理至关重要,特别是在低收入和中等收入国家 (LMICs).
- 痴呆症病例在LMICs急剧增加,需要更新的临床见解.
- 早期发现痴呆症有助于识别其他潜在的健康状况.
研究的目的:
- 在LMIC环境中,分析痴呆症患者的社会人口统计和临床特征.
- 分析该人口中痴呆症的诊断和治疗模式.
- 为在资源有限的环境中提供对痴呆症呈现的最新理解.
主要方法:
- 对192名被诊断患有痴呆症的老年人进行了回顾性队列研究.
- 从老年中心的心理老年和神经病诊所的医疗记录中收集的数据.
- 从案例记录中系统地提取信息.
主要成果:
- 参与者的平均年龄为74.0岁;97.9%的人与他人生活在一起.
- 高并发症率:有50.0%的人至少有一次,高血压 (64.1%) 和糖尿病 (22.4%) 是最常见的.
- 治疗迟到发生在52.6%的患者中;行为问题 (55.2%) 和遗忘 (91.7%) 是关键症状.
结论:
- 显著比例的痴呆症患者晚期出现多种并发症.
- 对老年人痴呆模式的临床意识对于及时干预至关重要.
- 调查结果强调,需要在LMIC中针对痴呆症护理采取量身定制的方法.
相关概念视频
Dementia
110
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
110
Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
Alzheimer's Disease: Treatment
178
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
178
Cognitive Development During Adulthood
87
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
87
Continuing Care
1.5K
Continuing care describes the variety of health, personal, and social services provided over a prolonged period. The need for continuing care is increasing because people are living longer. Many people do not have families or others to care for them. Continuing care is mainly for patients who are disabled, functionally dependent, or suffering from a terminal disease. It is available within institutional settings or in homes. Examples include nursing centers or facilities, assisted living,...
1.5K
Parkinson's Disease: Overview
523
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
523


